- The trend backdrop is active with a 8-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
THYROCARE
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Thyrocare Technologies Limited · Healthcare · Diagnostics & Research
Latest close
603.2 INR
4.2%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 32.8% above the Trend Line and sits at 94.8% of its 52-week range. The latest completed week returned 4.2%, after a 17.0% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 53/100. Near-term considerations: price is close to its 52-week high.
Setup score
68
out of 100
Latest Close
603.2 INR
7 Aug 2026
1W Return
4.2%
latest completed week
4W Return
17.0%
short-term follow-through
12W Return
32.2%
quarterly tape
Trend Breadth
63.5%
33 of 52 weeks active
Volume Ratio
1.0x
vs 13-week average
- 17 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
4.2%
Latest completed week; four-week move 17.0%.
Indicator stack
63/74
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
53/100
32 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 32.8% above the Trend Line and sits at 94.8% of its 52-week range. The latest completed week returned 4.2%, after a 17.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.8612-week average 0.60
12-week confirmation
Trend active8/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.86Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1717 reversal markers
No recent accumulation markers. 17 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 17.0% over four weeks, 32.2% over 12 weeks, and 36.1% over one year. The current trend has remained active for 8 consecutive weeks.
Performance by holding period
Active trend streak8 weeks
Active weeks in one year33
Trend breadth63.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.20Latest activity-pressure read.
Pressure change26.5%Four-week change in activity pressure.
Leadership35.46Latest relative-leadership reading.
RS change71.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength48/100Blend of value, momentum, and quality. Underlying universe rank 53; rank 1 is best.
Value8/100Relative valuation strength. Underlying universe rank 93; rank 1 is best.
Quality99/100Profitability and accounting quality. Underlying universe rank 2; rank 1 is best.
Momentum83/100Medium-term price momentum. Underlying universe rank 18; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework39/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 58.9x Price divided by trailing earnings.
- Price / sales
- 11.7x Market value relative to trailing revenue.
- EV / EBITDA
- 35.1x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 2.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 73.3% Gross profit retained from each unit of revenue.
- Operating margin
- 24.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 23.4% Free cash flow generated from revenue.
- Return on invested capital
- 25.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 20.7% Latest one-year revenue growth.
- EPS growth
- 78.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 31.4% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 1.5% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 1.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment53/100
Weighted news tone is neutral across 32 relevant articles.
7 positive · 22 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-2.3%Distance below the 52-week high.
13-week volatility4.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher16 of 2610 weeks finished lower.
Best week+21.5%Week of 8 May.
Worst week-7.2%Week of 10 Jul.
Latest week+4.2%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains10
Flat weeks0
Modest losses6
Sharp losses4
Recent vol4.7%13-week weekly-return volatility.
Base vol6.1%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew5.0% / -3.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank7 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Diagnostics & Research
4-week rank1 / 9
Group average4.7%
Trend breadth66.7%
Trend66.7%active weekly trend signals
MD77.8%positive activity pressure
RS66.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape64/100
Trend, activity pressure, participation, and risk combine to a 64/100 tape read.
Indicator analysis72/100Latest 12-week confirmation: trend 8/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.86; 17 reversal markers Factors59/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 61; Small Cap Core rank 89 SVQF39/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 965.5 of 1583 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment53/100Weighted news tone is neutral across 32 relevant articles.
Thyrocare Techn Consolidated June 2026 Net Sales at Rs 240.02 crore, up 24.34% Y-o-Y Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 603.2 INR | 4.2% | 454.1 INR | 314.1 INR | 1.20 | 35.46 | 2.7M | On |
| 31 Jul 2026 | 579.0 INR | 2.6% | 449.2 INR | 311.4 INR | 1.07 | 31.90 | 5.9M | On |
| 24 Jul 2026 | 564.2 INR | 8.4% | 445.2 INR | 308.8 INR | 1.01 | 32.71 | 14.7M | On |
| 17 Jul 2026 | 520.6 INR | 1.0% | 441.8 INR | 306.4 INR | 0.87 | 20.40 | 2.1M | On |
| 10 Jul 2026 | 515.7 INR | -7.2% | 439.0 INR | 304.3 INR | 0.95 | 20.66 | 1.5M | On |
| 3 Jul 2026 | 555.6 INR | 7.4% | 436.3 INR | 302.1 INR | 1.01 | 30.69 | 230.6K | On |
| 26 Jun 2026 | 517.2 INR | -3.1% | 431.4 INR | 299.6 INR | 0.97 | 24.07 | 0 | On |
| 19 Jun 2026 | 533.6 INR | 2.2% | 430.7 INR | 297.4 INR | 1.02 | 29.50 | 138.7K | On |
| 12 Jun 2026 | 522.1 INR | 2.1% | 430.0 INR | 294.9 INR | 0.96 | 30.13 | 331.8K | Off |
| 5 Jun 2026 | 511.3 INR | 2.3% | 430.0 INR | 292.6 INR | 0.93 | 30.12 | 89.5K | Off |
| 29 May 2026 | 499.8 INR | 8.7% | 428.4 INR | 290.3 INR | 1.04 | 27.58 | 2.2M | Off |
| 22 May 2026 | 459.9 INR | 0.8% | 427.3 INR | 288.0 INR | 0.70 | 17.54 | 1.5M | Off |
| 15 May 2026 | 456.2 INR | -5.0% | 426.0 INR | 286.0 INR | 0.31 | 17.83 | 2.0M | Off |
| 8 May 2026 | 480.2 INR | 21.5% | 424.5 INR | 284.1 INR | -0.12 | 22.26 | 13.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.